Mayo Clinic Pharmacy Grand Rounds

The Clot Thickens: Anticoagulation in ECMO

Hannah M. Brokmeier, PharmD (@hannahbrokmeier) compares and contrasts the pharmacokinetic and pharmacodynamic properties of heparin and bivalirudin in extracorporeal support, identifies clinical scenarios that favor either heparin or bivalirudin for anticoagulation in ECMO and selects a preferred agent for ECMO when either heparin or bivalirudin are acceptable.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Mu and Improved: Flushing Opioid-Induced Constipation Down the Drain

Danielle M. Hess, PharmD (@dhess_09) describes the pathophysiology of opioid-induced constipation (OIC), evaluates literature depicting the safety and efficacy of peripherally-acting mu-opioid receptor antagonists (PAMORAs) for the treatment of OIC and applies the clinical pearls of PAMORAs to patient care.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Medications for Alcohol Use Disorder

Audrey J. Umbreit, PharmD, BCACP describes alcohol use disorder (AUD) as a chronic disease, identifies evidence-based medications for treatment of AUD and selects a medication based on individual patient factors to treat AUD.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Probiotics or Conbiotics: Probiotic Use in Preterm Neonates

Brandi N. Smith, PharmD, BCPPS defines necrotizing enterocolitis and late-onset sepsis in the premature neonate and proposed mechanisms of prevention with probiotic use, reviews literature supporting the use of probiotics in premature neonates and recognizes ongoing questions in using probiotics in premature neonates.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Targeted Oral Chemotherapy Agents for Metastatic Breast Cancer

Kaitlyn J. Bailey, PharmD (@pharmgirl1821) describes the mechanisms of action of select CDK46, PI3K, and PARP inhibitors, reviews the outcomes data related to CDK46, PI3K, and PARP inhibitors for treatment of metastatic breast cancer and discusses toxicity management for CDK46, PI3K, and PARP inhibitors. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Shall We Bival? Use of Bivalirudin for Anticoagulation in Pediatric ECMO

Mai Uyen Alissa Le, PharmD describes the utility and importance of anticoagulation in ECMO, identifies clinical factors to consider with the use of bivalirudin anticoagulation in ECMO and discusses literature evaluating the use of bivalirudin and its comparison to heparin for anticoagulation in pediatric patients supported on ECMO. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Less is More: Integrating Deprescribing in the Inpatient Setting

Joseph C. Osborne III, PharmD (@JOzempic) describes the current framework of deprescribing, reviews literature pertinent to deprescribing in the inpatient setting and identifies facilitators, barriers, and future directions for deprescribing.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Mr. COVID & MIS-C: One Toxic Relationship

Natalie A. Haddad, PharmD (@NatalieHaddadRx) describes the epidemiology of multisystem inflammatory syndrome in children (MIS-C), outlines key similarities and differences between MIS-C and other comparable pediatric conditions and discusses current potential therapeutic options for the treatment of MIS-C.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Blast from the BARBiturate Past: Phenobarbital for Alcohol Withdrawal Syndrome

Kyle S. Wamsley, PharmD (@KyleWamsley1) describes the pathophysiology and complications associated with alcohol withdrawal syndrome (AWS), reviews treatment modalities and commonly utilized agents for AWS in the ICU setting and outlines appropriate phenobarbital dosing regiments based on current literature. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

CRASH-3 Into Me: Update in Management of Intracranial Hemorrhage

Erin D. Wieruszewski, PharmD, BCCCP (@EDWieru) describes the goals of treatment for intracranial hemorrhage, discusses literature examining the use of desmopressin and tranexamic acid for intracranial hemorrhage and identifies appropriate patients to receive treatment with desmopressin or tranexamic acid.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.